2026 NPPES data Hematology & Oncology Physician NPI 1245670173 M.D
Verify on CMS →

SAMER AL HADIDI, M.D

Hematology & Oncology Physician in DALLAS, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
253
Medicare Part D claims · 125 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
60%
generic claims · 40% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$11.4K
17 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: SAMER AL HADIDI, M.D is a Hematology & Oncology Physician ([object Object]) practicing in DALLAS, Texas with a Medicare Part D prescribing footprint of 253 claims across 125 beneficiaries — 40% brand-name prescribing . Industry payments of $11.4K across 17 transactions are disclosed under CMS Open Payments (Sunshine Act).

What stands out: SAMER AL HADIDI, M.D filed 253 Medicare Part D claims in 2023 across DALLAS, Texas. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board certification likely (heuristic — not verified)

SAMER AL HADIDI, M.D practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 2 hospital affiliations — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

SAMER AL HADIDI, M.D at a glance

Quality data not reported

NPI registry status

Active

Issued 06/25/2013

NPI 1245670173

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

253 70% vs specialty avg

2023 prescription claims

Specialty avg: 847

Specialty distribution in Texas

How Hematology & Oncology Physician compares to other specialties among Texas providers

Texas providers

Hematology & Oncology Physician share within Texas

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within Texas

Specialty board-certification context

Estimated specialty board-certified rate — Hematology & Oncology Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Hematology & Oncology Physician ABMS/AOA estimate

Est. board-certified rate (Hematology & Oncology Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Hematology & Oncology Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

SAMER AL HADIDI, M.D is a Hematology & Oncology Physician provider practicing in DALLAS, Texas, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D. NPI: 1245670173. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

SAMER AL HADIDI, M.D appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D credentials at 6202 HARRY HINES BLVD, DALLAS, TX, 75390, with a listed phone of (214) 645-3999. NPI 1245670173 was issued on 06/25/2013. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what AL HADIDI most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 253 prescription claims written by this provider, covering 125 Medicare beneficiaries and totaling roughly $1.8 million in drug spend, split 40% brand-name and 60% generic by claim count, with an opioid prescribing rate of 6.7%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

6202 HARRY HINES BLVD
DALLAS, TX 75390

Provider Details

NPI 1245670173
Specialty Hematology & Oncology Physician
Credentials M.D
Gender Male
NPI Issued 06/25/2013

Hospital and facility affiliations

Facilities where SAMER AL HADIDI, M.D bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES
LITTLE ROCK, AR
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
DALLAS, TX

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for SAMER AL HADIDI, M.D. Source: openpaymentsdata.cms.gov.

Total received

$11.4K

Largest payer

GENZYME CORPORATION

Most common payment type

Travel and Lodging

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to SAMER AL HADIDI, M.D. To verify SAMER AL HADIDI, M.D's current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

SAMER AL HADIDI, M.D — brand share 40.0%
Specialty average (est.)

40% brand-name claims vs 60% generic, on 253 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

253
Total Claims
$1.8M
Total Drug Cost
125
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
255
Total Day Supply
3,498
Brand vs Generic
40% brand / 60% generic
Brand Drug Cost
$1.5M
Generic Drug Cost
$312K
Opioid Claims
17 (6.7% rate)

Patient Demographics

Average Patient Age
72.2 years
Avg HCC Risk Score
2.32
Gender Split
50% female / 50% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Lorazepam
114
Revlimid
Lenalidomide
88
Lenalidomide
25
Morphine Sulfate
12

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How SAMER AL HADIDI, M.D fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

SAMER AL HADIDI, M.D's 253 claims are below the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as AL HADIDI.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is SAMER AL HADIDI, M.D's specialty?
SAMER AL HADIDI, M.D specializes in Hematology & Oncology Physician and practices in DALLAS, Texas. Credentials: M.D.
How much does SAMER AL HADIDI, M.D prescribe under Medicare Part D?
In 2023, SAMER AL HADIDI, M.D wrote 253 Medicare Part D claims totaling $1.8M in drug costs for 125 beneficiaries.
Where is SAMER AL HADIDI, M.D located?
SAMER AL HADIDI, M.D is located at 6202 HARRY HINES BLVD, DALLAS, TX, 75390. Phone: (214) 645-3999.
What is SAMER AL HADIDI, M.D's NPI number?
SAMER AL HADIDI, M.D's National Provider Identifier (NPI) is 1245670173, issued on 06/25/2013.
Does SAMER AL HADIDI, M.D prescribe more brand-name or generic drugs?
SAMER AL HADIDI, M.D's prescribing is 40% brand-name and 60% generic drugs by claim count, with $1.5M in brand drug costs.
Does SAMER AL HADIDI, M.D prescribe opioids?
Yes, SAMER AL HADIDI, M.D had 17 opioid claims in 2023 with an opioid prescribing rate of 6.7%.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does SAMER AL HADIDI, M.D prescribe most often?
Based on 2023 Medicare Part D data, SAMER AL HADIDI, M.D's most frequently prescribed drugs include Lorazepam, Revlimid, Lenalidomide. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does SAMER AL HADIDI, M.D accept Medicare?
SAMER AL HADIDI, M.D appears in CMS Medicare data with 253 Part D claims and 125 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify SAMER AL HADIDI, M.D's credentials?
SAMER AL HADIDI, M.D's NPI is 1245670173 with credentials M.D. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology